Patents by Inventor Arthur G. Taveras

Arthur G. Taveras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic aryl sphingosine 1-phosphate analogs
    Publication number: 20100160258
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 24, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • Heterotricyclic Metalloprotease Inhibitors
    Publication number: 20100087420
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: December 4, 2009
    Publication date: April 8, 2010
    Applicant: ALANTOS PHARMACEUTICALS HOLDINGS, INC.
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgürtel, Hongbo Deng, Brian M. Gallagher, JR., Irving Sucholeiki, Arthur G. Taveras
  • Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
    Patent number: 7691856
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: April 6, 2010
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Jianhua Chao, Purakkattle J. Biju, Younong Yu, Cynthia J. Aki, J. Robert Merritt, Ge Li, John J. Baldwin, Gaifa Lai, Minglang Wu, Evan A. Hecker
  • Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
    Patent number: 7671212
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, J. Robert Merritt, John J. Baldwin, Junying Zheng, Purakkattle J. Biju, Younong Yu, Jianhua Chao, Gaifa Lai, Minglang Wu
  • Heterobicyclic Metalloprotease Inhibitors
    Publication number: 20090312312
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: February 12, 2009
    Publication date: December 17, 2009
    Applicant: ALANTOS PHARMACEUTICALS HOLDING, INC.
    Inventors: Christoph STEENECK, Christian GEGE, Frank RICHTER, Heiko KROTH, Matthias HOCHGURTEL, Michael ESSERS, Joshua VAN VELDHUIZEN, Bert NOLTE, Brian M. GALLAGHER, JR., Tim FEUERSTEIN, Matthias SCHNEIDER, Torsten ARNDT, Hongbo DENG, Ralf BIESINGER, Xinyuan WU, Harald BLUHM, Irving SUCHOLEIKI, Arthur G. TAVERAS
  • 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
    Publication number: 20090306079
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Application
    Filed: January 13, 2009
    Publication date: December 10, 2009
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, JR., Laura L. Rokosz, Gaifa Lai, James P. Jakway, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
  • Thiadiazoles AS CXC- and CC- chemokine receptor ligands
    Patent number: 7338968
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: March 4, 2008
    Assignee: Schering Corporation
    Inventors: Purakkattle J. Biju, Arthur G. Taveras, J. Robert Merritt, John J. Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia J. Aki
  • CXCR1 and CXCR2 chemokine antagonists
    Patent number: 7326729
    Abstract: The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 5, 2008
    Assignee: Schering Corporation
    Inventors: Jianhua Chao, Arthur G. Taveras, Cynthia J. Aki
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Patent number: 7132445
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: November 7, 2006
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Jr., Laura L. Rokosz, James P. Jakway, Gaifa Lai, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
  • 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists
    Patent number: 6903131
    Abstract: Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: June 7, 2005
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Arthur G. Taveras, Michael Dwyer, Johan A. Ferreira, Viyyoor M. Girijavallabhan, Jianping Chao, John J. Baldwin, J. Robert Merritt, Ge Li
  • 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
    Patent number: 6878709
    Abstract: Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: April 12, 2005
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Arthur G. Taveras, Michael Dwyer, Jianping Chao, John J. Baldwin, J. Robert Merritt, Ge Li, Jianhua Chao, Younong Yu
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
    Publication number: 20040235908
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: June 16, 2004
    Publication date: November 25, 2004
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jonathan A. Pachter, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
  • Farnesyl protein transferase inhibitors
    Patent number: 6800636
    Abstract: Disclosed are compounds of the formula: wherein R8 represents a cyclic moiety to which is bound an imodazolylalkyl group; R9 represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: October 5, 2004
    Assignee: Schering Corporation
    Inventors: Timothy Guzi, Dinanath F. Rane, Alan K. Mallams, Alan B. Cooper, Ronald J. Doll, Viyyoor M. Girijavallabhan, Arthur G. Taveras, Corey Strickland, Joseph M. Kelly, Jianping Chao
  • Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands
    Publication number: 20040186142
    Abstract: Disclosed are novel compounds of the formula: 1
    Type: Application
    Filed: October 7, 2003
    Publication date: September 23, 2004
    Applicant: Schering Corporation Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Jianhua Chao, Purakkattle J. Biju, Younong Yu, Jay S. Fine, William Hipkin, Cynthia J. Aki, J. Robert Merritt, Ge Li, John J. Baldwin, Gaifa Lai, Minglang Wu, Evan A. Hecker
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Publication number: 20040147559
    Abstract: There are disclosed compounds of the formula 1
    Type: Application
    Filed: July 30, 2003
    Publication date: July 29, 2004
    Applicant: Schering Corporation and Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Laura L. Rokosz, James P. Jakway, Gaifa Lai, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Publication number: 20040106794
    Abstract: There are disclosed compounds of the formula 1
    Type: Application
    Filed: September 11, 2002
    Publication date: June 3, 2004
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Laura L. Rokosz
  • Farnesyl protein transferase inhibitors
    Patent number: 6740661
    Abstract: Disclosed are compounds of the formula: wherein R13 represents an imidazole ring; R14 represents a carbamate, urea, amide or sulfonamide group; R8 represents H when the alkyl chain between the amide group and the R13 imidazole group is substituted, or R8 represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl; and the remaining substituents are as defined herein. Also disclosed are compounds wherein R8 is H, and the alkyl chain between the amide group and the R13 imidazole group is unsubstituted. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 25, 2004
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, Ronald J. Doll, Alan B. Cooper, Johan A. Ferreira, Timothy Guzi, Alan K. Mallams, Dinanath F. Rane, Viyyoor M. Girijavallabhan, Adriano Afonso, Cynthia J. Aki, Jianping Chao, Carmen Alvarez, Joseph M. Kelly, Tarik Lalwani, Jagdish A. Desai, James J-S Wang, Jay Weinstein
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Publication number: 20040097547
    Abstract: There are disclosed compounds of the formula 1
    Type: Application
    Filed: July 30, 2002
    Publication date: May 20, 2004
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Kingsley H. Nelson, Laura L. Rokosz
  • 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
    Publication number: 20040063709
    Abstract: Disclosed compounds of the formula (I) 1
    Type: Application
    Filed: January 2, 2003
    Publication date: April 1, 2004
    Applicant: SCHERING CORPORATION
    Inventors: Arthur G. Taveras, Michael Dwyer, Jianping Chao, John J. Baldwin, J. Robert Merritt, Ge Li, Jianhua Chao, Younong Yu
  • Treatment of chemokine mediated diseases
    Publication number: 20040053953
    Abstract: Methods of treating chemokine-mediated diseases are disclosed.
    Type: Application
    Filed: March 17, 2003
    Publication date: March 18, 2004
    Applicant: Schering Corporation
    Inventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu